Siliconrepublic.com | Opsona Therapeutics Limited raises an additional ?3 million (US $4 million ... 4-traders (press release) Dr. Bruno Montanari, Life Sciences Director, Omnes Capital, added: "I am looking forward to progressing Opsona's lead product OPN-305 through the well-designed Phase II efficacy study to prevent delayed graft function (DGF) in renal transplantation, an ... Opsona Therapeutics raises €3m (US$4m) in Series C extension round |
